Gastric Cancer: Recombinant RTN2 was used to demonstrate its role in promoting metastasis via ERK signaling. Overexpression in gastric cancer cells increased migration and invasion by 2.5-fold, driven by calcium release from ER stores .
Mechanism: RTN2 binds inositol 1,4,5-trisphosphate receptor (IP3R), triggering Ca²⁺ efflux and epithelial-mesenchymal transition (EMT) .
Amyloid Regulation: RTN2 inhibits β-secretase (BACE1), reducing amyloid-β production in Alzheimer’s models .
Glucose Transport: Enhances SLC2A4/GLUT4 translocation to cell membranes, facilitating glucose uptake .
Calcium Imaging: RTN2 reduced RyR2-mediated Ca²⁺ oscillations in neurons by 40% .
Transwell Migration: Gastric cancer cells transfected with RTN2 showed 3-fold higher invasion compared to controls .
Co-IP/MS: Pull-down assays identified IP3R and ERK1/2 as binding partners .
Recombinant Human Reticulon-2 (RTN2) inhibits amyloid precursor protein processing, likely by blocking BACE1 activity. It enhances trafficking of the glutamate transporter SLC1A1/EAAC1 from the endoplasmic reticulum to the cell surface. Furthermore, it plays a role in the translocation of SLC2A4/GLUT4 from intracellular membranes to the cell membrane, facilitating glucose uptake.